STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease

Argenx said its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder.